Manufacturing execution system (MES) technical maturity is rising, but adoption across manufacturing sites is uneven. Organizational readiness may hold the key.
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Can A Biotech Create A CDMO Market?
- Why Are Life Science Companies So Poorly Prepared For RIM's Future?
- April 2026 — CDMO Opportunities And Threats Report
- Cell And Gene Therapies: The Emerging Reality For Scalable Market Readiness
- Tackling The Cell & Gene Therapy Sector's Practical Post-Approval Problem
- Why Your MES RFP Is Failing Before It Starts
- Here's How FDA's Accelerated Approval Pathway Has Evolved Since '24
CELL & GENE ARTICLES, APP NOTES, CASE STUDIES, & WHITE PAPERS
-
Evaluating The Expression Patterns Of Multiple Inhibitory Receptors
Discover how an innovative approach to interpreting T-cell exhaustion and inhibitory receptor expression is paving the way for innovative therapeutic approaches aimed at rejuvenating T-cell function.
-
Commercial Success Starts With A Fit-For-Purpose Flow Cytometer
Discover how standardizing reagents and automating flow cytometry workflows can improve reproducibility, reduce troubleshooting, and accelerate progress in cell-based therapies.
-
Demonstration Of Scalability For A Novel Fixed Bed Reactor Platform
Designed to enable efficient scalability, a new FBR platform allows operators to use one technology, with a standardized workflow, for their process development, scale-up, and manufacturing processes.
-
Global Regulatory Harmonization: Comparisons In Aseptic Barrier Systems
Compare global aseptic standards from the FDA, EMA, PIC/S, and WHO. Gain insights into how advanced barrier systems harmonize international requirements to ensure sterile product integrity and safety.
-
Addressing The Challenges In Lentivirus Harvest Clarification
Traditional depth filtration struggles with lentiviral harvest clarification, leading to low yields and high costs. However, single-use centrifugation offers a promising alternative.
-
Transforming Clinical Trial Management
See how Vestigo® can transform your study management — streamline workflows, strengthen compliance, and eliminate inefficiencies by adopting a smarter, digital-first approach today.
-
Scalability From 5L To 50L Using The DynaDrive Single-Use Bioreactor
Maintaining a consistent bioprocess when scaling from 5 L to 50 L is achievable. This study shows how to successfully scale processes while maintaining cell density, viability, and protein production.
-
Standardize Flow Cytometry Data With Easy Assay Transfer Across Sites
Gain insight into how a global pharmaceutical company successfully transferred their cell therapy assays across international locations.
-
Innovating The mAb Characterization Process
Understanding the characteristics of a molecule's "personality" is crucial for optimizing development and manufacturing. Learn how to overcome the challenges in the characterization process.
-
Rapid, Seamless Upstream Process Development And Scale-Up For CHO-K1 Cells
Accelerate your biotech company's scale-up process while delivering consistent and strong cell growth, productivity, and product quality.
NEWSLETTER ARCHIVE
- 05.14.26 -- Early CDMO Engagement For Cell Therapies? CellProthera's CEO Thinks Not
- 05.13.26 -- Manufacturing Moves Shaping Advanced Therapies
- 05.13.26 -- How MTP Is Transforming Pharma Production Lines
- 05.13.26 -- Rewriting Disease Biology Through LSD1 Inhibition
- 05.12.26 -- West Vantage: End-to-End Combination Product Solutions
- Dr. Peter Marks On Why Gene Therapy May Need A New Regulatory Playbook
- Regeneron Advances In Vivo Gene Therapy For Hearing Loss
- Sana, Mayo Clinic Advance A New Model For Cell Therapy Delivery In T1D
- Reprogramming T-Cell Access To Solid Tumors Through Improved Trafficking And Entry
- Target Selection Drives The Future Of CAR T Therapy In Solid Tumors
CELL AND GENE CONTENT COLLECTIONS
While there are opportunities to scale, there are also manufacturing gaps, capacity issues, and production timelines that require improvement to do so. And then, of course, there’s cost. Because scale up and scale out are significant to everyone in the sector, we’ve curated insightful editorial that addresses the most important aspects of scalability.
More Content Collections